Pd 1 And Pd L1 Inhibitors - Cancer Science

Relevant Publications

Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.

Issue Release: 2024

Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances.

Issue Release: 2024

Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.

Issue Release: 2024

Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virus.

Issue Release: 2024

Immune profiling of mouse lung adenocarcinoma paraffin tissues using multiplex immunofluorescence panel: a pilot study.

Issue Release: 2024

Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by F-BMS986-192 PET: pooled analysis of data from four solid tumor types.

Issue Release: 2024

γδ T cells and the PD-1/PD-L1 axis: a love-hate relationship in the tumor microenvironment.

Issue Release: 2024

Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome.

Issue Release: 2024

PDL1 targeting by miR-138-5p amplifies anti-tumor immunity and Jurkat cells survival in non-small cell lung cancer.

Issue Release: 2024

Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer.

Issue Release: 2024

Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors.

Issue Release: 2024

Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive -mutant Non-small Cell Carcinoma.

Issue Release: 2024

Prognostic value of programmed cell death ligand 1 (PD-L1) expression in patients with stage III non-small cell lung cancer under different treatment types: a retrospective study.

Issue Release: 2024

Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer-Narrative Review.

Issue Release: 2024

Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications.

Issue Release: 2024

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare mutations: a real-world retrospective study.

Issue Release: 2024

Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy.

Issue Release: 2024

Histopathological, Molecular and Clinical Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder (LELC-B).

Issue Release: 2024

Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group.

Issue Release: 2024

Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions.

Issue Release: 2024

What are the Symptoms of Hepatotoxicity?

Can Smoothies and Shakes Help with Side Effects?

How Are Treatment Decisions Made?

How Does Histopathology Contribute to Clinical Correlation?

What are the Challenges in Developing Cancer Drug Candidates?

Which MMPs are most commonly associated with Cancer?

What are the Benefits of Cancer Audits?

What Precautions are Necessary?

What Are the Common Types of Topical Anesthetics?

How to Ensure Compliance?

Pd 1 And Pd L1 Inhibitors - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics